Conditions: Pancreatic Disease
Keywords: Genetic End Marker
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 64
Healthy volunteers: no

Brief summary:
The following are the study hypothesis:

* Secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples being predominantly of exocrine pancreas origin when samples are duodenal aspirates.
* Secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples meeting the minimum specifications for use in the indicated laboratory test of DNA mutational analysis.

Detailed description:

Arms:
arm 1: Human Secretin for Injection arm 2: Saline for Injection

Interventions: intervention 1: ChiRhoStim intervention 2: Placebo
Intervention descriptions: intervention 1: Human Secretin for Injection intervention 2: Saline for Injection

Protocol document: